Mark Yarchoan, MD, Johns Hopkins Medicine

Articles

Selecting Therapy for Advanced HCC Following TKI Failure

August 10th 2022

Shared insight on which factors help to inform selection of second-line therapy for patients with advanced HCC following lenvatinib failure.

Patient Profile 3: Second-Line Therapy for Advanced HCC

August 10th 2022

Centering discussion on a patient with advanced HCC, expert oncologists consider which agents they would use in the second line following lenvatinib failure.

Frontline Therapy for Advanced HCC: Novel Combination Strategies

August 3rd 2022

Before closing out their discussion on frontline therapy for advanced HCC, expert panelists review other novel combinations under investigation.

Frontline Lenvatinib versus Sorafenib Treatment in Advanced HCC

August 3rd 2022

Comprehensive insight on the selection and use of frontline tyrosine kinase inhibitors for patients with advanced hepatocellular carcinoma.

Role of Hepatitis Status in Selecting Therapy for HCC

July 27th 2022

Expert panelists briefly review how a patient’s hepatitis status may influence treatment selection for advanced hepatocellular carcinoma.

Real-World Selection of Frontline Combination Therapy for Advanced HCC

July 27th 2022

Taking into account respective data from IMbrave150 and HIMALAYA, experts consider how they might select frontline therapy for advanced HCC.

HIMALAYA: Frontline Durvalumab + Tremelimumab in Advanced HCC

July 20th 2022

Shared insight on combination durvalumab + tremelimumab as frontline therapy for advanced HCC in the context of data from the HIMALAYA trial.

Patient Profile 2: Frontline Therapy for Advanced HCC

July 20th 2022

Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.

Management of HCC: Advances in Biomarkers and Screening

July 13th 2022

A brief review of predictive and prognostic biomarker needs in hepatocellular carcinoma, followed by discussion on screening and detection.

Selection and Use of Systemic Therapy in Intermediate Stage HCC

July 13th 2022

Panelists consider the role of systemic therapy in patients with intermediate-stage HCC who are ineligible for locoregional therapy.

Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

July 6th 2022

Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

Early-Stage HCC: What is the Role of Neoadjuvant Therapy?

July 6th 2022

Expert oncologists consider when it would be appropriate to use neoadjuvant therapy for early-/intermediate-stage hepatocellular carcinoma.

Early-Stage HCC: Role of Adjuvant Therapy

June 29th 2022

A brief discussion on the risks of neoadjuvant immunotherapy in early-/intermediate-stage HCC with regard for liver transplantation candidacy.

Patient Profile 1: Resection for Early/Intermediate Stage HCC

June 29th 2022

Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy, respectively.

Dr. Yarchoan on Unique Characteristics of Fibrolamellar Carcinoma

October 22nd 2021

Mark Yarchoan, MD, discusses unique characteristics of fibrolamellar carcinoma.

Optimizing Precision Medicine in HCC

October 1st 2021

Takeaways from a discussion on treatment advances in hepatocellular carcinoma.

Biomarkers to Guide HCC Treatment Decisions

October 1st 2021

Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.

Second-Line Treatment Approaches for Advanced HCC

September 24th 2021

An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.

The COSMIC-312 Study in Advanced HCC

September 24th 2021

Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.

HCC: IO in Liver Transplant Recipients

September 17th 2021

A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.